Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition used for treating hepatitis

A composition and drug technology, applied in the direction of drug combination, medical formula, plant raw materials, etc., can solve the problems of long treatment cycle, high recurrence rate, and single effect, and achieve non-toxic and side effects, good therapeutic effect, and remarkable effect

Active Publication Date: 2014-06-25
CP PHARMA QINGDAO CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the research and application of traditional Chinese medicine for the treatment and prevention of hepatitis are extensive, the curative effect of traditional Chinese medicine for the treatment of hepatitis is not significant, the effect is single, the pertinence is poor, the treatment cycle is long, the recurrence rate is high, and it cannot treat both the symptoms and the root causes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition used for treating hepatitis
  • Medicine composition used for treating hepatitis
  • Medicine composition used for treating hepatitis

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0029] Observation object and method

[0030] 1. Case selection

[0031] (1) Etiological diagnosis

[0032] Type A: Those who have any one of the following four items:

[0033] 1. Serum anti-HAVIgM positive in patients with acute hepatitis;

[0034] 2. The anti-HAVIgG titer of the double serum in the acute phase and the recovery phase increased by more than 4 times;

[0035] 3. HAV particles were detected by anti-HAV immuno-electron microscopy in feces in the early acute stage;

[0036] 4. HAAg was found in feces in the early acute stage.

[0037] Type B: Those who have any one of the following four items:

[0038] 1. Serum HbsAg positive, or HbeAg positive;

[0039] 2. Serum HbsAg positive, but anti-HbcIgM positive, or anti-HBs, or anti-HBc positive;

[0040] 3. Serum HBV-DNA or DNA polymerase positive, or HbeAg, or anti-Hbe positive;

[0041] 4. The indicators of HBV infection are not obvious or only one indicator of anti-HBc is positive, while HbcAg, HbsAg or HBV-DN...

experiment example 2

[0117] Experimental Example 2: Pharmacodynamics Experiment

Embodiment 1

[0131] Embodiment 1 capsule

[0132] Kelp extract 3kg Eucheuma extract 1kg

[0133] Morinda officinalis 50kg, 30kg of scorpion vine.

[0134] Add 15 times the amount of water to Morinda officinalis and Tachibana, soak for 36 hours; decoct twice with slow fire, the first time for 2 hours, filter the liquid medicine for later use, add 10 times the amount of water for the second time, and use Simmer for 1 hour, filter the medicinal liquid for use; combine the secondary medicinal liquids for filtration, and collect the filtrate; concentrate the filtrate to a thick paste with a relative density of 1:1.25-1.35, and bake the thick paste at low temperature for 10 hours to obtain Dry cream powder, mix the dry cream powder with kelp extract and Eucheuma extract: add excipients at a weight ratio of 1:0.5 to starch, granulate, dry at 50°C, granulate and pack into capsules. Capsule specification: 0.2g / grain, 2 tablets of Example 1 a day

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine composition used for treating hepatitis. The composition is composed of a kelp extract, a muricate eucheuma extract, medicinal morinda root, and Chinese starjasmine stem. According to the invention, the raw materials of the medicine composition are decocted by using water; the obtained mixture is filtered and concentrated; and the obtained product is prepared into clinically acceptable tablets, capsules, granules, pellets, or oral liquids. The medicine composition provided by the invention has the functions of liver soothing, liver nursing, and liver protecting. The medicine composition has good treatment effects against acute hepatitis A, acute hepatitis B, chronic persistent hepatitis, chronic active hepatitis, and the like. The effects are substantial, and no toxic or side effect is caused.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating hepatitis, a preparation method and a new application thereof. Background technique [0002] Hepatitis includes acute and chronic hepatitis, chronic persistent hepatitis and chronic active hepatitis. It is a common and frequently-occurring disease, especially the liver disease caused by hepatitis B virus, which seriously endangers people's health. It is easy to develop into liver cirrhosis and even transform into liver cancer. Liver disease, especially hepatitis B, is one of the most common infectious diseases in the world. According to relevant reports, nearly 1 million people die each year due to liver disease. my country is a country with a high incidence of liver disease. At present, there are about 30 million patients with chronic hepatitis B. And 120 million hepatitis B virus carriers, accounting for more than 10% of the total populat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/746A61K9/48A61P1/16A61P31/14A61P31/20
CPCY02A50/30
Inventor 王明刚任莉陈阳生
Owner CP PHARMA QINGDAO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com